Eudaimonia Partners’s BioNTech BNTX Stock Holding History

Eudaimonia Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-225	Closed	-$25K	–	493
2021 Q1	$25K	Sell	225 -48	-18%	-$5.1K	0.01%	866
2020 Q4	$22K	Buy	+273	New	+$26.8K	﹤0.01%	835

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Eudaimonia Partners's BNTX Position: Q2 2021 in Review

Eudaimonia Partners sold out of BioNTech (BNTX) in Q2 2021, closing a stake of 225 shares — an estimated $25K sold.

Eudaimonia Partners first reported a position in BNTX in Q4 2020 and held it in 2 quarters. The position peaked at $25K in Q1 2021. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2021.

Eudaimonia Partners reported no remaining BioNTech position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 225 BioNTech shares in Q2 2021, an estimated $25K.
Eudaimonia Partners first reported a position in BioNTech in Q4 2020 and held it in 2 quarters.
Eudaimonia Partners's BioNTech position peaked at $25K in Q1 2021.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.